Paul Ehrlich's magic bullet concept: 100 years of progress

@article{Strebhardt2008PaulEM,
  title={Paul Ehrlich's magic bullet concept: 100 years of progress},
  author={K. Strebhardt and A. Ullrich},
  journal={Nature Reviews Cancer},
  year={2008},
  volume={8},
  pages={473-480}
}
  • K. Strebhardt, A. Ullrich
  • Published 2008
  • Medicine
  • Nature Reviews Cancer
  • Exceptional advances in molecular biology and genetic research have expedited cancer drug development tremendously. The declared paradigm is the development of 'personalized and tailored drugs' that precisely target the specific molecular defects of a cancer patient. It is therefore appropriate to revisit the intellectual foundations of the development of such agents, as many have shown great clinical success. One hundred years ago, Paul Ehrlich, the founder of chemotherapy, received the Nobel… CONTINUE READING
    785 Citations

    Figures and Topics from this paper

    Precision Medicine and Complexity
    Emerging Therapeutic Strategies in Breast Cancer
    • 3
    Tailoring the Treatment of Melanoma: Implications for Personalized Medicine
    • 3
    Cancer immunotherapy: Breakthrough or “deja vu, all over again”?
    • S. Sell
    • Medicine
    • Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
    • 2017
    • 9
    Targeting active cancer cells with smart bullets
    • S. Martel
    • Computer Science, Medicine
    • Therapeutic delivery
    • 2017
    • 10
    • PDF

    References

    SHOWING 1-10 OF 166 REFERENCES
    Antibody targeted drugs as cancer therapeutics
    • 664
    • PDF
    Immunotoxin therapy of cancer.
    • 126
    Improving the efficacy of antibody-based cancer therapies
    • 805
    • PDF
    The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics.
    • 300
    Expanding the repertoire of RNA interference screens for developing new anticancer drug targets
    • S. Haney
    • Biology, Medicine
    • Expert opinion on therapeutic targets
    • 2007
    • 13
    Strategies to overcome resistance to targeted protein kinase inhibitors
    • 316
    • PDF
    Novel radiolabeled antibody conjugates
    • 59
    • PDF
    Maximizing mouse cancer models
    • 623
    Cancer revoked: oncogenes as therapeutic targets
    • D. Felsher
    • Biology, Medicine
    • Nature Reviews Cancer
    • 2003
    • 264
    • PDF